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Solution conformation of an essential region of the p53
transactivation domain
Maria Victoria E Botuyan1, Jamil Momand2 and Yuan Chen1
Background: The peptide segment surrounding residues Leu22 and Trp23 of
the p53 transactivation domain plays a critical role in the transactivation activity
of p53. This region binds basal transcriptional components such as the
TATA-box binding protein associated factors TAFII40 and TAFII60 as well as the
mdm-2 and adenovirus type 5 E1B 55 kDa oncoproteins. 
Results: The structure of residues 14–28 of p53 was studied by nuclear
magnetic resonance spectroscopy and found to prefer a two-β-turn structure
stabilized by a hydrophobic cluster consisting of residues known to be
important for transactivation and binding to p53-binding proteins. A peptide
segment in which Leu22 and Trp23 were replaced by Gln and Ser displays a
random structure.
Conclusions: This structural propensity observed in the wild-type p53 peptide
is important for understanding the mechanism of transcriptional activation,
because very few structural data are available on transactivation domains to
date. These results should aid in the design of therapeutics that could
competitively inhibit binding of p53 to the oncogene product mdm-2.
Introduction
The p53 tumor suppressor protein is a checkpoint protein
that responds to cellular stress [1,2]. p53 directly binds and
upregulates genes that arrest the cell cycle or activate an
apoptotic pathway [3,4]. The N-terminal 40 amino acid
residues of p53 are capable of conferring transactivation
function when fused onto a heterologous DNA-binding
domain [5–7]. The p53 transactivation domain binds
TFIID, the multimeric protein complex responsible for
directing RNA polymerase II-mediated transcription.
Polypeptides within TFIID such as the TATA-box
binding protein (TBP) and two TBP-associated factors
(TAFs), TAFII40 and TAFII60, have been shown to
specifically bind p53 [8–11]. This p53 domain also binds
proteins that inhibit its transactivation. Mdm-2, a cellular
oncoprotein upregulated in a variety of cancers [12,13],
and the adenovirus oncoprotein E1B 55 kDa (E1B 55K)
have been shown to block p53-mediated transactivation
[14,15] through binding this p53 domain [16–19].
Extensive mutagenesis studies have identified residues
14–28 of p53 as a critical region for transactivation and
binding of these proteins [7,9–11,18]. A peptide corre-
sponding to residues 16–25 of p53 was shown to indepen-
dently bind mdm-2 [19]. It is not unexpected that this
short peptide can duplicate this function of intact p53, as
circular dichroism (CD) and proteolytic digestion studies
revealed that the p53 transactivation domain does not
have a compactly folded tertiary structure [7,20]. In this
situation, the local structure and function of a peptide
segment is not affected by distal residues. Therefore, struc-
tural and functional properties of a peptide corresponding
to this region of p53 (residues 14–28) should be similar to
those in an intact p53 molecule. This region of p53 also con-
tains an antibody-binding site [19]. A number of immuno-
genic and antigenic peptides have been shown to have
conformational preferences for structured forms [21].
Although the conformational preferences of short linear
peptide fragments may not always reflect their conforma-
tions when bound to receptor proteins or in the original
proteins, many studies have shown that the structural
propensity, detected by CD or NMR spectroscopy, often
reflects the conformations of a peptide in the original
protein or when bound to a physiological receptor [22,23].
If a peptide prefers a conformation similar to its recep-
tor-bound state, it will more readily bind to the receptor
compared to a peptide that lacks structural propensity. If a
peptide lacks structural propensity, it must search for a
large number of possible conformations to find the recep-
tor-bound one, a process that is both time and entropy
consuming. Similarly, if a peptide has the propensity to
form a conformation similar to that in the native protein, it
can serve as a nucleation site in protein folding [24,25].
The structure of a peptide corresponding to residues
15–29 of p53 bound to mdm-2 has been studied by X-ray
crystallography [26]. The conformation of a peptide corre-
sponding to residues 17–24 of p53 when bound to mdm-2
has also been investigated by transfer NOE studies [27].
The conformations of p53 bound to TAFII40, TAFII60
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and oncoprotein E1B 55K have not been reported,
however. The structural preference of the critical region of
p53, residues 14–28, may reflect the conformations of p53
in complexes with these proteins. Knowledge of the struc-
tural propensity of this region of p53 in the free form
would improve our understanding, on the molecular level,
of the mechanisms by which p53 interacts with TFIID
and oncoproteins mdm-2 and E1B 55K. 
Many peptides have been shown to have structurally pre-
ferred conformations, although most short linear peptides
are completely random in solution. The structural propen-
sity of peptides may originate from the intrinsic prefer-
ences of amino acid residues for certain dihedral angles
[28]. The propensity may also result from amino acid side-
chain interactions that lead to a deviation of the backbone
dihedral angles from random-coil values [29]. The princi-
ples for predicting conformational propensities in peptides
on the basis of their amino acid sequences are still under
intensive study. 
In order to evaluate the conformational propensities of
the Leu14–Glu28 region of p53, we conducted NMR
studies on a synthetic peptide (LSQETFSDLWKLL-
PE) of human p53. We found that this region has a sig-
nificant propensity to cooperatively form two successive
β turns stabilized by a hydrophobic cluster. Previous
studies showed that the double substitution Leu22→Gln
Trp23→Ser is the only mutation, thus far, that curtails
p53 interactions with the TAFs, mdm-2 and E1B 55K, as
well as p53-mediated transactivation. We also examined
the conformational properties of an identical length syn-
thetic peptide where Leu22 and Trp23 were replaced by
Gln and Ser (LSQETFSDQSKLLPE). We found that
the mutant peptide is completely random, due to the
disruption of the hydrophobic cluster.
Results
Evaluation of sample conditions
Short linear peptides may aggregate at high concentra-
tions. In order to determine that the peptides being
studied are in the monomeric form under the conditions of
our NMR studies, the NMR measurements were con-
ducted at peptide concentrations from 0.2 mM to 10 mM.
No concentration-dependent changes in proton chemical
shifts, resonance linewidths or NOEs have been observed.
In addition, the linewidths of proton resonances of both
the wild-type and mutant p53 peptides are appropriate for
monomeric forms of both peptides. 
In order to further confirm that the peptides being studied
are in the monomeric forms, the diffusion coefficients of
the peptides at 10 mM concentration were measured using
the pulsed-field gradient method [30]. The gradient field
strengths were calibrated carefully using a 2 mM lysozyme
sample (Ds = 1.08 × 10–6 cm2/s at 25°C). Ten gradient
strengths were used as described in the Materials and
methods section and the resulting spectra are shown in
Figure 1a. The plots of ln(echo amplitudes), ln(A), versus
the square of the gradient field strengths, g2, are shown in
Figure 1b for both the wild-type and mutant p53 peptides
measured at 2°C and for lysozyme measured at 25°C. The
diffusion coefficients of the wild-type and mutant p53 pep-
tides are 1.23 × 10–6 and 1.15 × 10–6 cm2/s, respectively, at
2°C. The hydrodynamic radii estimated from the diffusion
coefficients are similar to those of monomeric peptides of
similar sizes measured by light scattering at 20°C [31].
Resonance assignments of the wild-type and mutant p53
peptides were performed using the established approaches
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Figure 1
(a) Stack plots of the pulsed-field NMR spectra at 10 gradient (g)
strengths: 3.68, 5.52, 7.36, 9.92, 11.0, 12.9, 14.7, 16.6, 18.4, and
20.2 Guass/cm. The sample contained 10 mM wild-type p53 peptide
dissolved in D2O with 10 mM sodium phosphate buffer, pH 6.0.
(b) Plots of ln(echo amplitudes), ln(A), versus the square of the
gradient field strengths, g2, of the wild-type and mutant p53 peptides
and lysozyme. The data for lysozyme were acquired at 25°C, and the
data for the peptides were acquired at 2°C.
10.2 9.6 9.0 8.4 7.8 7.2
1H (ppm)
3.68
g 
(G
/c
m
)
7.36
11.0
14.7
18.4
5004003002001000
1
2
3
4
5
g2
ln
(A
)
Wild-type p53
Mutant p53
Lysozyme
(a)
(b)
Folding & Design
[32]. The proton chemical shifts are referenced to
2,2-dimethyl-2-silapentane-5-sulfonic acid (DSS). Finger-
print regions of the DQF-COSY spectra of the wild-type
and mutant p53 peptides are shown in Figure 2. Residues
18–25 display the largest differences (≥ 0.06 ppm) in the
αH chemical shifts between the wild-type and the mutant
p53 peptides. The amide proton chemical shifts of residues
20–26 differ by more than 0.1 ppm between the two pep-
tides. Residues at both termini have similar backbone
proton chemical shifts between the two peptides, however.
Only one strong crosspeak for each residue has been found.
Several smaller crosspeaks with intensities less than 5% of
the major peaks have also been observed. These peaks
may result from impurities or minor conformations. 
The differences between the peptide backbone proton
chemical shifts and their random-coil values provide an
estimation of their secondary structures [33]. Deviations of
αH chemical shifts from the random-coil values for the
wild-type and mutant p53 peptides are shown in Figure 3a.
Both αH and NH random-coil chemical shifts are taken
from Wishart and Sykes [33]. The αH protons from
residues 18–25 of the wild-type p53 peptide are uniformly
upfield-shifted, whereas the αH chemical shifts of the
mutant peptide are randomly distributed and generally
close to the random-coil values. The αH resonance of
residue 26 is shifted downfield by 0.29 and 0.34 ppm in the
wild-type and mutant p53 peptides, respectively, presum-
ably due to the presence of Pro27 [34]. It has been found
that the mean deviation of αH chemical shifts from the
random-coil values for the 20 naturally occurring amino
acids is –0.39 ppm when placed in a helical configuration.
In the β-strand configuration, this mean deviation is 0.37
ppm. The observed uniformly upfield-shifted αH chemi-
cal shifts of the wild-type peptide may indicate some pref-
erence for the α-helical configuration. No deviations are
larger than 0.3 ppm, however, indicating that the wild-type
peptide has no strong tendency for α-helix formation. The
deviation of NH chemical shifts from random-coil values
gives information on hydrogen bonding. Partial desolvation
of an NH proton or formation of an intramolecular hydro-
gen bond, which has a lower strength than hydrogen bonds
with solvent water molecules, results in upfield-shifted NH
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Figure 2
Fingerprint regions of the DQF-COSY spectra of (a) wild-type and
(b) mutant p53 peptides. The spectra were taken at 2°C with samples
in 90%H2O/10%D2O and 10 mM sodium phosphate buffer, pH 6.0.
8.8 8.6 8.4 8.0 7.88.2
4.
7
4.
5
4.
3
4.
1
4.
6
4.
4
4.
2
4.
0
S15
Q16
E17
E28
F19
D21
L26
T18
S20
L25
L22
W23
K24
S15
Q16 Q17/E28
D21
F19 L26
S20
Q22
S23
K24
T18
L25
D1 (ppm)
D
2
 (p
pm
)
D
2
 (p
pm
)
(a)
(b)
Folding & Design
Figure 3
Plots of the difference in NMR chemical shift (observed – random coil)
for (a) αH and (b) NH versus residue number. The filled bars and open
bars correspond to the wild-type and mutant peptides, respectively.
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resonances relative to the random-coil values. The devia-
tion of amide proton chemical shifts from random-coil
values of both the wild-type and mutant p53 peptides are
shown in Figure 3b. Residues 22–25 of the wild-type p53
peptide are significantly upfield shifted, indicating partial
desolvation or formation of intramolecular hydrogen bonds
by these residues.
NOEs, coupling constants and temperature coefficients
A series of NOESY spectra with mixing times ranging from
50 to 500 ms were recorded for the wild-type peptide in
order to find the appropriate mixing time for structural
analysis. It was found that the 300 ms mixing time is in the
linear region of the NOE build-up curve. Therefore, NOEs
were analyzed from the 300 ms mixing time NOESY spec-
trum. Characteristic sequential and medium-range NOEs
give information about secondary structures. In β strands,
dαN(i,i+1) NOEs are observed, but dNN(i,i+1) NOEs are
generally not observed. In helical structures, both NOEs
can be observed. Additionally, dαβ(i,i+3) and dαN(i,i+3)
NOEs are characteristic for helical conformations. A
schematic diagram showing the sequential and medium-
range NOEs between backbone protons is presented in
Figure 4. The dαN and dNN regions of the NOESY spec-
trum of the wild-type p53 peptide are shown in Figure 5.
Sequential dαN and dNN connectivities have been observed
for the wild-type and the mutant p53 peptides. The pres-
ence of both dNN(i,i+1) and dαN(i,i+1) NOE connectivities
indicates that the conformational ensembles of the pep-
tides in solution have no tendency for forming extended β
strands. Although both dNN(i,i+1) and dαN(i,i+1) NOEs can
be observed in helical structures, characteristic dαβ(i,i+3) or
dαN(i,i+3) NOEs were not detected. Detection of some of
these NOEs could be hampered by signal overlapping. But
the signals that are not in the overlapped region, for
example the dαN(i,i+3) NOE between Ser20 and Trp23,
were not observed. Thus, it appears that there is no strong
tendency for the peptides to form a helical conformation.
The peptide bond proceeding Pro27 appears to be mainly in
the trans conformation, because the dαδ NOE was observed
but no detectable dαα NOE was observed.
Evidence for turn structures in the wild-type p53 peptide
has been found. Two dαN(i,i+2) NOEs have been observed
between Ser20 and Leu22 and between Trp23 and Leu25
in the wild-type peptide. In addition, the dNN(i,i+2) NOEs
have also been observed for the two pairs of residues
(Figure 5). In type I and type II β turns, dαN(i,i+2) distances
between residues 2 and 4 are 3.2 Å and 3.6 Å, respectively.
The dNN(i,i+2) distances between residues 2 and 4 are 3.8 Å
and 4.3 Å, respectively. Both turns have strong dNN(3,4)
NOEs. The two types of turns may be distinguished by
comparing the intensities of dNN(2,3) and dαN(2,3) NOEs.
The dNN(2,3) is stronger than the dαN(2,3) NOE in type I
turns, and the reverse for type II turns. The dαN NOE
intensities are stronger than that of the dNN(2,3) between
residues 20 and 21 and between residues 23 and 24. These
data suggest type II turns, but the coupling constants,
discussed below, are not consistent with type II turns. 
Although the mutant p53 peptide has only two amino acid
substitutions, medium-range or long-range NOEs were not
observed for either the backbone protons or the sidechain
protons. This suggests that the mutant peptide does not
have detectable structural propensity. This is consistent
with the backbone proton chemical shifts being similar to
random-coil values.
Although i to i+2 NOEs between backbone protons may
be observed even when the peptide displays random-coil
structures due to transient encounter of these protons [35],
coupling constant measurements of the wild-type p53
peptide provide strong support that the wild-type p53
peptide deviates significantly from the random-coil struc-
ture. The JHNα coupling constants were measured for 13
residues of the wild-type p53 peptide. Phe19, Leu22 and
Trp23 have coupling constants between 5 Hz and 6 Hz
(Figure 4). These coupling constants are significantly
below the intrinsic coupling constants for these residues in
a random-coil structure [36,37], indicating that appreciable
conformational preference exists around residues 19, 22
and 23. These residues are part of both turns suggested by
NOE data. Coupling constants for other residues are all
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Figure 4
Schematic diagram showing the sequential
and medium-range NOEs between backbone
protons. Also shown are coupling constants,
3JHNα, in Hz (±1.2 Hz) and temperature
coefficients, ∆δ, in ppb/K (±0.3 ppb/K). The
light-gray box indicates the connectivity
observed to δH of the Pro residue in place of
the amide proton.
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between 6 Hz and 8 Hz. These coupling constants do not
agree with either type I or type II turns. Additional evi-
dence for the conformational preference of the wild-type
p53 peptide is provided by temperature coefficients. The
temperature dependence of an amide proton chemical
shift is an indication of protection from solvent, often by
hydrogen bonds. Burial due to proximity of a bulky aroma-
tic sidechain can also cause a small temperature coefficient
[23]. For a random-coil peptide in water, the temperature
coefficients of the amide protons are expected to be
between 6 ppb/K and 10 ppb/K. For structured peptides
having amide protons protected from the solvent, the
temperature coefficients are generally below 6 ppb/K.
Residues Leu22 to Leu25 have the lowest temperature
coefficients among all residues in the peptide (Figure 4),
suggesting that the amide protons of these residues may
be better protected from the solvent than the other resi-
dues in the peptide. Other than Lys24, the temperature
coefficients of residues Leu22–Leu25 are close to 6 ppb/K,
also indicating significant conformational flexibility. Protec-
tion of the amide protons from the solvent suggested by
temperature coefficients is consistent with amide proton
chemical shift deviations from random-coil values.
Other strong evidence that the wild-type p53 peptide
deviates significantly from a random-coil structure comes
from many additional medium-range and long-range
NOEs observed for this peptide, in addition to the
medium-range NOEs described above (Figure 4). In par-
ticular, many NOEs have been observed among the back-
bone and sidechain protons of four hydrophobic and
aromatic residues: Phe19, Leu22, Trp23 and Leu25
(Table 1). These NOEs would not be expected for a
random-coil structure. A region of the 300 ms mixing time
NOESY spectrum shown in Figure 6 demonstrates some
of these NOEs. These observations indicate that a
hydrophobic cluster tends to be formed by these residues.
Interactions among these residues appear to be important
for stabilizing the structural propensity of the wild-type
p53 peptide. From a qualitative analysis of the NOEs
involving the four hydrophobic and aromatic residues,
however, it is not clear how these residues may interact
with one another. In order to obtain a better understand-
ing of the structural propensity of the p53 peptide and
how the hydrophobic residues may interact with each
other, structures of this peptide were calculated based on
observed NOE and coupling constant data. 
Structure calculation of the wild-type p53 peptide
Linear peptides are generally very flexible and exist as a
conformational ensemble of a large number of widely dif-
ferent conformers in aqueous solution. Conformational para-
meters obtained from NOE and coupling constants are
population-weighted average values. Therefore, complete
characterization of all the conformations of a short linear
peptide in aqueous solutions has been difficult and
remains an area of active study. In many cases, one partic-
ular structure or family of structures cannot satisfy all
NOE and coupling constant constraints, so calculations
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Figure 5
NOESY spectrum of wild-type p53 peptide showing the (a) dαN and
(b) dNN regions. The characteristic NOEs for turn structures are
indicated. The spectrum was acquired at 2°C with 10 mM wild-type
p53 peptide in 90%H2O/10%D2O, 10 mM sodium phosphate, pH 6.0.
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assuming multiple conformers need to be performed
[38–40]. In the calculation with the wild-type p53 peptide,
it was first assumed that all the nonsequential NOEs and
nonrandom coil coupling constants result from one family
of structures with a significant population. The resulting
family of structures has favorable molecular mechanics
336 Folding & Design Vol 2 No 6
Table 1
NOEs among Phe19, Leu22, Trp23 and Leu25 in wild-type p53
at pH 6.0, 2°C.
Phe19 αH Leu22 δCH3(1)
Phe19 αH Leu22 δCH3(2)
Phe19 αH Leu25 δCH3(1)
Phe19 αH Leu25 δCH3(2)
Phe19 β2H Leu22 β2H
Phe19 β2H Leu22 β3H
Phe19 β3H Leu22 β2H
Phe19 β3H Leu22 β3H
Phe19 β2H Leu22 δCH3(1)
Phe19 β2H Leu22 δCH3(2)
Phe19 β3H Leu22 δCH3(1)
Phe19 β3H Leu22 δCH3(2)
Phe19 β2H Leu25 δCH3(1)
Phe19 β2H Leu25 δCH3(2)
Phe19 β3H Leu25 δCH3(1)
Phe19 β3H Leu25 δCH3(2)
Phe19 2,6H Leu22 NH
Phe19 2,6H Leu22 β2H
Phe19 2,6H Leu22 β3H
Phe19 2,6H Leu22 δCH3(1)
Phe19 2,6H Leu22 δCH3(2)
Phe19 2,6H Leu25 δCH3(1)
Phe19 2,6H Leu25 δCH3(2)
Phe19 3,5H Leu22 δCH3(1)
Phe19 3,5H Leu22 δCH3(2)
Phe19 3,5H Leu25 δCH3(1)
Phe19 3,5H Leu25 δCH3(2)
Phe19 3,5H Trp23 4H
Phe19 3,5H Trp23 7H
Leu22 αH Trp23 NH
Leu22 αH Trp23 2H
Leu22 αH Leu25 δCH3(1)
Leu22 αH Leu25 δCH3(2)
Leu22 β2H Leu22 δCH3(1)
Leu22 β2H Leu22 δCH3(2)
Leu22 β2H Trp23 NH
Leu22 β3H Trp23 NH
Leu22 β3H Trp23 6H
Leu22 NH Trp23 NH
Leu22 NH Trp23 4H
Leu22 δCH3(1) Trp23 NH
Leu22 δCH3(2) Trp23 NH
Leu22 δCH3(1) Trp23 βH
Leu22 δCH3(2) Trp23 βH
Leu22 δCH3(1) Trp23 4H
Leu22 δCH3(2) Trp23 4H
Leu22 δCH3(1) Trp23 5H
Leu22 δCH3(2) Trp23 5H
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Trp23 7H Leu25 δCH3(1)
Trp23 7H Leu25 δCH3(2)
Figure 6
NOESY spectrum of the wild-type p53 peptide showing some NOEs
among the hydrophobic and aromatic sidechains. The sample
contained 10 mM p53 peptide dissolved in D2O with 10 mM
phosphate buffer, pH 6.0.
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energies and low constraint violations (Table 2). A few
additional NOE constraints (approximately six) that were
not used in the calculation were the weakest and had
intensities close to the noise level. It is possible that these
NOE constraints arose from minor conformations. The
calculated structures are consistent with the covalent
geometry and all experimental data, including coupling
constants, that are not explicitly included in the calcula-
tion. Therefore, this family of structures may represent a
significant population of structured conformers of the
wild-type p53 peptide and provide further understanding
of the mechanism of how the structure may be stabilized. 
The backbone fold of the structures of the p53 peptide is
shown in Figure 7. The 15 molecular dynamics refined
structures from the 50 DIANA structures with the lowest
constraint violations were used for detailed analysis. Statis-
tics for the family of structures are summarized in Table 2.
The conformation of the polypeptide backbone between
residues Phe19 and Leu25 is well defined, whereas the
residues close to both termini exhibit high disorder. The
well-defined structure for the region Phe19–Leu25 is due
to numerous nonsequential NOE constraints and dihedral
angle constraints. In fact, all nonsequential NOE con-
straints observed are among the backbone and sidechain
protons within residues Phe19–Leu25 (Figure 8).
The segment Phe19–Leu25 forms two turns as shown in
the superposition of the backbone fold of the family of
structures (Figure 7). The first turn runs from Phe19 to
Leu22; the second turn commences at Leu22 and termi-
nates at Leu25. The Φ and Ψ angles of the first turn
exhibit considerable flexibility. For residues Ser20 and
Asp21, the Φ angles range from –141° to 99° and from
–115° to –56°, respectively. The measured 3JHNα coupling
constants for Ser20 and Asp21 are 7.3 Hz and 7.0 Hz,
respectively, which are consistent with the Φ angles.
Although it is not possible to assign the turn type of
residues 19–22 based on the backbone dihedral angles of
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Figure 7
Stereoview of the backbone conformation of
15 structures of the wild-type p53 peptide.
The structures are superimposed to minimize
the root mean square deviation of the
backbone C′, Cα and N atoms of residues
Phe19–Leu25.
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Table 2
NMR structure statistics.
(a) NMR constraints
Distance constraints 234
Intraresidue 111
Sequential (i–j = 1) 73
Medium range (1 < i–j ≤ 4) 40
Long range (i–j > 4) 10
Dihedral angle constraints 3
Φ 3
(b) Structure statistics
NOE constraint violations per structure:
Number > 0.1 Å 1.20 ± 1.01
Maximum violations (Å) 0.12 ± 0.03
Maximum dihedral angle violations 3.22 ± 1.39
AMBER energy (kcal/mol) –130.54 ± 9.12
Van der Waals’ energy (kcal/mol) –55.46 ± 4.97
Angle energy (kcal/mol) 23.86 ± 1.87
Bond energy (kcal/mol) 2.93 ± 0.13
(c) RMS deviations from the mean structure
Backbone heavy atoms (N, CA, C′, O)
Residues 1–15 2.51
Residues 6–12 0.79
All heavy atoms
Residues 1–15 3.02
Residues 6–12 0.91
individual structures, the average Φ and Ψ angles of all
structures (average Φ angles for residues 20 and 21 are –21°
and –86°, and Ψ angles are –39° and –35°, respectively)
agree best with a type III turn [41]. The backbone dihedral
angles of Trp23 and Lys24 are better defined. The Φ
angles of Trp23 and Lys24 range from –64° to –35° and
from –74° to –55° and are both consistent with the mea-
sured 3JHNα coupling constants of 5.5 Hz and 6.8 ± 1.2 Hz,
respectively. The Φ dihedral angles of other residues are
all consistent with the measured 3JHNα coupling constants.
In particular, residues at both C and N termini have 3JHNα
values reflective of the high conformational flexibility in
these regions.
As indicated by NOE data, a hydrophobic cluster is
formed by residues Phe19, Leu22, Trp23 and Leu25. The
superposition of sidechain heavy atoms of residues 19–25
in the family of structures is shown in Figure 9a and a
space-filling model of a representative structure is shown
in Figure 9b. The sidechain of Leu22 packs on the aro-
matic rings of Phe19 and Trp23. The two aromatic
residues also interact closely with each other. Residue
Leu25 interacts with both aromatic rings and with Leu22.
The hydrophobic interactions and aromatic ring stacking
effect are responsible for stabilization of the structure of
residues 19–25. The amide proton of Lys24 is partially
buried in the hydrophobic cluster and protected from the
solvent, consistent with its low temperature coefficient
and upfield-shifted amide proton chemical shift. A sec-
ondary stabilization factor appears to be the charge inter-
action between Asp21 and Lys24. These two oppositely
charged residues flank the hydrophobic cluster composed
of residues Phe19, Leu22, Trp23 and Leu25. The
sidechain of Lys24 is slightly ordered due to interactions
with the hydrophobic cluster; the γH of Lys24 has NOEs
with the ring protons 1H, 4H and 5H of Trp23. Close
interaction of the Lys24 γH is also evident from the
unusually upfield-shifted chemical shift (1.09 ppm). 
Discussion
The double-turn structure
This study shows that the essential region of the p53
transactivation domain, residues 14–28, tends to form two
β turns and is stabilized both by hydrophobic/aromatic and
charged interactions. Interactions among amino acid
sidechains have been found to play important roles in sta-
bilizing structures in other short peptides or local struc-
tures in denatured proteins. These induce conformational
preferences of amino acid residues to deviate from
random-coil structures. In particular, hydrophobic and aro-
matic amino acid interactions appear to be important in
stabilizing structures in aqueous solution. For example,
urea-denatured 434 repressor contains a hydrophobic
cluster that is formed by residues Val54, Val56, Trp58 and
Leu59 [42]. The hydrophobic cluster results in the obser-
vation of a significant number of medium-range NOEs,
which would not be expected for a random coil. Other
examples of structures stabilized by hydrophobic and aro-
matic interactions include a 16-residue peptide forming a
β hairpin [43] and a six-residue peptide forming a type VI
turn [44]. Interactions involving charged sidechains can
also play an important role in stabilizing secondary struc-
tures. This is shown in the S-peptide from ribonuclease A,
where sidechain interactions between i to i+4 Phe and
His, Glu and Lys, and Glu and Asp stabilized the helical
structure in the peptide [45]. The structure of the
wild-type p53 peptide provides further understanding of
the mechanism by which conformational preferences of
peptides are defined by the primary sequence.
The two β turns within the p53 transactivation domain
appear to form cooperatively. This is demonstrated by the
significant number of NOEs involving residues from both
turns. Hydrophobic/aromatic interactions and charge inter-
actions stabilizing the double-turn structure involve
residues from both turns. A large number of NOEs were
observed between the sidechains of Phe19 and Trp23 and
between the sidechains of Phe19 and Leu25. Also, the
sidechain protons of Leu22 have numerous NOEs to the
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Figure 8
Plot of the number of NOE constraints versus residue number of the
wild-type p53 peptide. Intraresidue NOEs, sequential NOEs,
medium-range NOEs (between residues that are 2–4 residues apart in
the primary sequence), and long-range NOEs (between residues that
are five or more residues apart in the primary sequence) are indicated.
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sidechain protons of Phe19, Trp23 and Leu25. The two
residues, Asp21 and Lys24, that appear to be involved in
electrostatic interaction also belong to two different turns.
These data indicate that the two turns form cooperatively.
To the best of our knowledge, this is the first short linear
peptide in which a two-turn structure is preferred. 
Structural propensity and bound conformations
Our studies indicate that the peptide segment Leu14–
Glu28 of p53 has the propensity to form two reverse-turn
structures with the functionally important residues Phe19,
Leu22, Trp23 and Leu25 forming a hydrophobic cluster.
Phe19, Leu22 and Trp23 maintain 100% identity among
all the p53 sequences known to date, and Leu25 is con-
served in p53 molecules from most species [46]. Substitu-
tions Leu22→Gln and Trp23→Ser result in the loss of the
structural propensity of the p53 peptide. The loss of the
structural propensity is clearly due to the disruption of the
hydrophobic cluster, but not the intrinsic preference of
their backbone conformation. In a random peptide, the
predicted distribution of Leu in α-helical conformation is
53% and in a β-strand conformation is 42% [37]. The
intrinsic distribution of Gln in α-helical and β-strand con-
formations is 57% and 34%, respectively. Trp and Ser are
equally populated between α-helical and β-strand confor-
mations in a random-coil peptide. Thus, the amino acid
substitutions do not change the intrinsic preferences for
the backbone dihedral angles of the peptide. Instead, these
substitutions perturb the hydrophobic interactions between
the amino acid sidechains. Substitutions at residues 22 and
23 severely limit transcriptional activation and impair p53
binding to TFIID, mdm-2 and E1B 55K (Figure 10). From
the structure of the p53–mdm-2 complex [26], Trp23
makes critical contacts with mdm-2. The substitutions not
only disrupt the structural propensity of the wild-type p53
peptide, but would also be predicted to disrupt one of the
important contacts with mdm-2.
On the basis of the structures of the free p53 peptide and
the p53 peptide in complex with mdm-2, we propose a
mechanism for the binding of p53 with mdm-2. In the
crystal structure of a p53 peptide–mdm-2 complex, resi-
dues 18–26 of the p53 peptide form a helical structure [26].
In the solution structures of the free peptide, this same
region favors two type III β turns with Φ and Ψ angles
similar to those of helices. For example, the Φ angles of
residues 19, 21, 22, 23 and 24 in the calculated structures
are –68 ± 10º, –86 ± 29º, –64 ± 11º, –50 ± 15º, and –64 ± 10º,
respectively. The Ψ angles of residues 20 and 21 are
–39 ± 29º and –24 ± 10º, respectively. These dihedral
angles do not need to change significantly upon mdm-2
recognition. Three residues of the p53 transactivation
domain, Phe19, Trp23 and Leu26, make critical contacts
with mdm-2. Phe19 and Trp23 in the free peptide are in a
poised position for recognition by mdm-2. Some residues
within the double-turn region of the free p53 peptide
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Figure 9
(a) Sidechain orientations from residues
Phe19–Leu25 of 15 solution structures of the
wild-type p53 peptide. The structures have
been superimposed by the root mean square
best fit of the backbone atoms of these
residues. Backbone atoms are shown in pink,
and sidechains are labeled. (b) Space-filling
model showing the hydrophobic interaction of
residues Phe19, Leu22, Trp23 and Leu25.
The two charged residues, Asp21 and Lys24,
are located on opposite sides of the
hydrophobic cluster.
appear to have high flexibility. For example, the Φ angles
of residues 20 and 25 are –21 ± 120º and –69 ± 59º, respec-
tively. The Ψ angles of residues 22, 24 and 25 are 143 ± 88º,
–16 ± 49º and –13 ± 74º, respectively. Upon mdm-2 bind-
ing, Leu22 interacts with mdm-2 without a significant
change in its orientation and stabilizes the backbone dihe-
dral angles around it into helical configurations. The
binding of the third critical residue, Leu26, to mdm-2 sta-
bilizes the dihedral angle around Leu25 and induces a
change in the orientation of Leu25. Mutagenesis data have
shown that mutation of Leu25 to Ala significantly reduces
the affinity of p53 to mdm-2, although it does not form
contacts with mdm-2 in the complex [19]. Based on the
structural propensity of the free peptide, the sidechain of
Leu25 helps to stabilize the hydrophobic cluster and may,
thus, be required for proper presentation of the hydrophobic
residues to mdm-2. 
The structural propensity of the free peptide is reflected
in the bound conformation when the peptide is in
complex with mdm-2. In both the free and mdm-2-
bound p53 peptide, the backbone conformations are
similar. In addition, the sidechains of Phe19, Leu22 and
Trp23 have similar relative orientations and maintain
their contacts. In the NMR study of the bound confor-
mation of a p53 peptide in complex with mdm-2, hydro-
phobic clustering of Phe19, Leu22, Trp23 and Pro24
(Lys24 was replaced by a Pro in this study) has also been
observed as studied by transfer NOE methods [27]. The
bound conformation of p53 when complexed with
mdm-2 reflects the inherent structural propensity of the
free p53 peptide, and this propensity may also be
preserved when p53 is in complexes with TAFII40,
TAFII60 and E1B 55K.
Structure and transactivation
The position pattern of Phe19, Leu22 and Trp23 is con-
served among several transcription factors containing
acidic, glutamine-rich or proline-rich domains [7,47]. An
extensive alignment of such domains, shown to be critical
for transactivation function, is presented in Figure 10b.
One transactivator within this class that has been analyzed
in some detail is VP16 expressed by herpes simplex virus
type I [47]. The Leu22 counterpart of p53, Phe442 of the
VP16 transactivation domain (A), could be replaced with
Tyr but not Ser or Ala for effective transactivation. This
suggests that a bulky hydrophobic residue at this position
is critical for this function. The transactivation domain of
VP16 can substitute for the N terminus of p53 to mediate
transcriptional activation as well as downstream functions
such as cell cycle arrest and apoptosis [48,49]. Another
transactivation domain within this class is the AH peptide
[50] (see Figure 10b). This 15 amino acid peptide can
confer transactivation activity when fused onto the GAL4
DNA-binding domain. Further studies are needed to
establish whether similar structural propensities exist
within other proteins that regulate transcription through
binding TFIID.
Materials and methods
Sample preparation
The 15 amino acid residue peptides LSQETFSDLWKLLPE (wild-type
p53) and LSQETFSDQSKLLPE (mutant p53) were synthesized by
solid phase method and purified by reverse phase HPLC. The amount
of each peptide was calculated from the absorbance of Phe19 at
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Figure 10
(a) Summary of mutagenesis data for p53
binding to several p53-binding proteins and for
transactivation. Underlined residues are in the
double-turn structure. ‘Transact.’ denotes
transactivation activity. Plus signs denote
residues that, when replaced singly or in
combination with a second residue, inhibit
binding to the indicated protein or prevent
transactivation by at least 70%. Transactivation
data are from [7,18], E1B 55K binding data
from [18], mdm-2 binding data from [18,19,57],
and TAFII40 and TAFII60 binding data from
[9–11]. (b) Alignment of the p53 transactivation
domain with other transactivation domains
(based on the original data from [7,47]).
Boldface residues in the p53 sequence share
100% identity across all species reported to
date [46]. Boxed regions indicate conservation
of bulky hydrophobic residue positions.
Information on the transactivation domains is
from the following sources: RelA III [58], GCN4
[59], B17 [60], human foamy virus (HFV) Bel1
transactivation domain (TAD) [61], HAP4 (1)
[62], AH [50], GAL4 [63], VP16 TAD (A) [47],
VP16 TAD (B) [64], Sp1 (A) and (B) [65].
14 15 16 17 18 19 20 21 22 23 24 25 26 27 28
L S Q E T     F     S      D     L       W     K     L L P E
E1B 55 K +  + + + + +
mdm-2 + + + +  + +
TAFII40 + + +  +
TAFII60 +  +
Transact. + +  + + +
p53   14 L S Q E T F S D L  - W K L L P E 28
RelA III 535  I A D M D F S A L  - L S Q  I S S 549
GCN4 271 D N S K E W T S L  - F D N D  I P 285
B17   15 P E E S Q F Q T W  - L N A V  I 29
HFV Bel1 TAD 115 S G G P F W E E V  - Y G D S  I L 129
HAP4 (1) 458 Y L P P T L E E L  - M E E Q D C 472
AH     3 Q E L Q E L Q A L  - L Q Q Q 15
GAL4 (1) 164 M P R D A L H G F D W S E E D D 179
GAL4 (2) 841 T D Q T A Y N A F G  I T T G M F 856
VP16 TAD (A) 434 A H A D A L D D F D L D M L G D 449
VP16 TAD (B) 465 Y G A L D M A D F E F E Q H F T 480
Sp1 (A) 156 G L P G V M P N  I Q Y Q V  I P Q 171
Sp1 (B) 452 N G Q V S W Q T L Q L Q N L Q V 467
(a)
(b)
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255 nm using the extinction coefficient value of 162 OD/mmol.
Samples contained approximately 0.2–10 mM of the wild-type or the
mutant p53 peptides, in either D2O or 90%H2O/10%D2O of 10 mM
sodium phosphate buffer, pH 6.0.
NMR measurements
NMR spectra were acquired on a Varian Unity-plus spectrometer oper-
ating at 500 MHz for protons. Internal 2,2-dimethyl-2-silapentane-5-sul-
fonic acid (DSS) was used as the proton chemical shift reference.
Most experiments were carried out at 2°C. TOCSY [51] experiments
were also done at 5, 10, 15 and 20°C for temperature coefficient mea-
surements. A PE-COSY experiment [52] was performed on the
wild-type peptide sample in D2O. The Jαβ coupling constants were
measured for residues with nondegenerate βH resonances. Only
residue Leu22 gave Jαβ coupling constants of 4 Hz and 10 Hz corre-
sponding to the two βH protons. Due to overlap of the γH resonance
with one of the βH resonances of Leu22, however, further determina-
tion of the χ1 dihedral angle for Leu22 was not performed. Other
residues gave coupling constants around 7 Hz, indicative of conforma-
tional averaging. NOESY, TOCSY and DQF-COSY experiments were
performed on both D2O and 90%H2O/10%D2O solubilized samples of
the wild-type and mutant peptides. The NOESY spectra were collected
using 50–500 ms mixing times. The TOCSY spectra were acquired
using isotropic mixing times of 30 ms and 70 ms. All spectra were
processed using Felix 95 software (Molecular Simulations, Inc.).
The diffusion coefficients of the peptides were measured using the
pulsed-field gradient method [30]. Ten gradient strengths, 3.68, 5.52,
7.36, 9.92, 11.0, 12.9, 14.7, 16.6, 18.4 and 20.2 Guass/cm, were
used in the measurements. In the gradient experiments, Shigemi NMR
tubes (Shigemi, Inc., Japan) were used, wherein 1 cm length samples
were centered along the radio frequency coil (1.5 cm long). This war-
rants that the sample is in the linear region of the gradient strength. The
ln(echo amplitudes), ln(A), were plotted versus the square of the gradi-
ent strengths, g2. The slope of these plots can be used to calculate
diffusion coefficients (Ds) as given by equation 1:
Generation of constraints
Distance information was obtained from NOESY spectra at 300 ms
mixing time, on both D2O and 90%H2O/10%D2O samples of the
wild-type peptide. Distance constraints were determined from cross-
peak volumes by calibration against known distances. Upper bounds
were assigned as 3.0, 3.7, 4.0, 5.0 and 6.0 Å. On these upper bounds,
pseudoatom corrections were incorporated in the calculation of initial
structures with the program DIANA [53]. In the refinement of these initial
structures with the program AMBER [54], distance corrections were
achieved by r–6 averaging. Lower bounds were the van der Waals’
radii. Dihedral angle constraints were obtained from coupling constant
measurements. From the DQF-COSY spectrum, 3JHNα were deter-
mined for 13 residues ([55]; Figure 4). Residues having 3JHNα < 6 Hz
have their Φ angles constrained to –90° to 40° in the DIANA calcula-
tions, and –90° to –40° in the AMBER calculations. In the AMBER calcula-
tions, the ω angles of the peptide backbone were constrained in all
cases to be 180° ± 5°. The peptide bond preceding Pro27 is mainly in
the trans conformation.
Structure calculations
Initial peptide structures were calculated with the program DIANA [53]
using the redundant dihedral angle constraint (REDAC) strategy [56]. To
the 50 initial randomized structures, three cycles of REDAC were applied
followed by a single cycle using only experimental constraints.
All 50 structures generated by DIANA had target functions from 0.19 to
1.13 and were then refined using a combination of energy minimization
and restrained molecular dynamics with the AMBER program. In these
calculations, the charge of residues Lys, Asp and Glu were reduced by
80% and a distance-dependent dielectric constant was used to
account for calculation in vacuum. The first energy minimization con-
sisted of 200 steps after which the target temperature was increased
to 1200K for 4 ps. The structures were then annealed for 10 ps with a
target temperature of 0K, followed by a 1 ps energy ‘quench’. The final
phase of the refinement consisted of 200 steps of conjugate gradient
energy minimization. During the initial energy minimization and the first
3 ps of molecular dynamics, the force constant for the distance con-
straint violations was increased from 0 to 32 kcal/(Å2 mol) and main-
tained at this value throughout the annealing and final minimization
steps. The force constant for dihedral angle constraint violations was
also increased in a similar manner as above from 0 to 20 kcal/mol for
Φ. For the chirality and ω angle constraints, the force constants were
set to 50 and 20 kcal/mol, respectively. 
Supplementary material
Chemical shift assignments and NOE buildup curves of a few typical
crosspeaks are provided as supplementary material.
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